Transcript Complement - Microbiology Book

Complement: History
Discovered in 1894 by
Bordet
It represents lytic activity
of fresh serum
Its lytic activity destroyed
when heated at 56C
for 30 min
Complement functions
• Host benefit:
–
–
–
–
–
–
opsonization to enhance phagocytosis
phagocyte attraction and activation
lysis of bacteria and infected cells
regulation of antibody responses
clearance of immune complexes
clearance of apoptotic cells
• Host detriment:
– Inflammation, anaphylaxis
Proteins of the complement
system (nomenclature)
• C1(qrs), C2, C3, C4, C5, C6, C7, C8, C9
• factors B, D, H and I, properdin (P)
• mannose binding lectin (MBL), MBL associated
serine proteases (MASP-1 MASP-2)
• C1 inhibitor (C1-INH, serpin), C4-binding
protein (C4-BP), decay accelerating factor
(DAF), Complement receptor 1 (CR1), proteinS (vitronectin)
Definitions
• C-activation: alteration of C proteins such that they
interact with the next component
• C-fixation: utilization of C by Ag-Ab complexes
• Hemolytic units (CH50): dilution of serum which
lyses 50% of a standardized suspension of Ab-coated
r.b.c
• C-inactivation: denaturation (usually by heat) of an
early C-component resulting in loss of hemolytic activity
• Convertase/esterase: altered C-protein which acts
as a proteolytic enzyme for another C-component
Activation product of complement
proteins (nomenclature)
Activated component are usually over-lined: e.g.
C1qrs
When enzymatically cleaved, the larger moiety,
binds to the activation complex or membrane
and the smaller peptide is released in the
microenvironment
Letter “b” is usually added to the larger,
membrane-binding, peptide and “a” to the
smaller peptide (e.g., C3b/C3a, C4b/C4a,
C5b/C5a), EXCEPT C2 (the larger, membranebinding moiety is C2a; the smaller one is C2b)
Pathways of complement
activation
CLASSICAL
PATHWAY
antibody
dependent
LECTIN
PATHWAY
ALTERNATIVE
PATHWAY
antibody
independent
Activation of C3 and
generation of C5 convertase
activation
of C5
LYTIC ATTACK
PATHWAY
Components of the Classical
Pathway
C3
C1 complex
C4
Classical Pathway
Generation of C3-convertase
Classical Pathway
Generation of C3-convertase
_____
C4b2a is C3 convertase
C4b
Classical Pathway
Generation of C5-convertase
________
C4b2a3b is C5 convertase;
it leads into the Membrane
Attack Pathway
C4b
C3b
Biological Activities of Classical
Pathway Components
Component
Biological Activity
C2b
Prokinin; cleaved by plasmin to yield kinin, which
results in edema
C3a
Anaphylotoxin; can activate basophils and mast
cells to degranulate resulting in increased vascular
permeability and contraction of smooth muscle cells,
which may lead to anaphylaxis
C3b
Opsonin
Activation of phagocytic cells
C4a
Anaphylaotoxin
C4b
Opsonin
12
Control of Classical Pathway
Components
Component
Regulation
All
C1-inhibitor (C1-INH); dissociates C1r and C1s from
C1q
C3a
C3a-inactivator (C3a-INA; Carboxypeptidase B)
C3b
Factors H and I; Factor H facilitates the degradation
of C3b by Factor I
C4a
C3a-INH
C4b
C4 binding protein (C4-BP) and Factor I; C4-BP
facilitates degradation of C4b by Factor I; C4-BP
also prevents the association of C2a with C4b thus
blocking formation of C3 convertase
13
Components of mannose-binding
lectin pathway
MBL
MASP1
Mannose-binding lectin pathway
_____
C4b2a is C3 convertase; it
will lead to the generation of
C5 convertase
MASP1
MBL
Components of the
alternative pathway
C3
Spontaneous C3 activation
Generation of C3 convertase
C3 i
b
C3b
C3iBb complex has a very short half life
C3-activation
the amplification loop
If spontaneously-generated
C3b is not degraded
C3b
b
C3 b
C3-activation
the amplification loop
C3 b
C3b
b
C3b
C3-activation
the amplification loop
C3 b
b
C3b
C3b
C3b
C3-activation
the amplification loop
C3b
C3b
C3b
C3b
C3-activation
the amplification loop
C3b
C3b
C3b
Control of spontaneous
C3 activation via DAF
DAF prevents
C3b
the binding of
factor B to C3b
CR1
Autologous cell membrane
Control of spontaneous
C3 activation via DAF
DAF dislodges
C3b-bound
factor Bb
b
C3b
CR1
Autologous cell membrane
Control of spontaneous
C3 activation via CR1
C3b
C3b
CR1
iC3b
CR1
Autologous cell membrane
Degradation of spontaneously
produced C3b
C3c
C3b
C3dg
iC3b
C3c
C3b
C3dg
iC3b
C3b stabilization and
C5 activation
C3b finds an activator
(protector) membrane
This is stable C5 convertase
of the alternative pathway
C3b
b
C3 b
C3b regulation on self and
activator surfaces
C3b
C5-convertase of the two
pathways
C5-convertase of the
Classical and lectin
Pathways
C3b
C4b
C5-convertase of the
Alternative Pathway
C3b
C3b
Lytic pathway
Generation of C5 convertase
leads to the activation of the
Lytic pathway
Components of the lytic pathway
C7
C6
C
9
Lytic pathway
C5-activation
b
C4b
C3b
Lytic pathway
assembly of the lytic complex
C6
C7
b
Lytic pathway:
insertion of lytic complex into cell membrane
C6
C7
CC C C
C9 9 9 9C
9C C C9
9 9 9
b
Biological effects of C5a
Adhesion
Neutrophil
Neutrophil
Vascular wall
transmigration
Chemotaxis
Neutrophil
Mast
cell
Monocyte
Activation
Degranulation
Neutrophil
Cytokine
Vascular permeability production
Activation
Respiratory burst
Biological properties of C-activation
products
Product
C2b
(prokinin)
C3a
(anaphylatoxin)
Biological Effects
edema
Regulation
C1-INH
mast cell degranulation; carboxypeptidase- B
enhanced vascular
(C3-INA)
permeability;
anaphylaxis
Biological properties of C-activation
products
Product
Biological Effects
Regulation
C3b
(opsonin)
opsonization;
phagocyte activation
factors H & I
C4a
as C3, but less
(anaphylatoxin) potent
(C3-INA)
C4b
(opsonin)
C4-BP,
factor I
opsonization;
phagocytosis
Biological properties of C-activation
products
Product
Biological Effects
Regulation
C5a
(chemotactic
factor)
anaphylactic as C3, but
much more potent;
attracts & activates PMN
causes neutrophil
aggregation, stimulation
of oxidative metabolism
and leukotriene release
carboxypeptidase-B
(C3-INA)
C5b67
chemotaxis, attaches
to other membranes
protein-S
Complement Deficiencies and Disease
Classical Pathway
Pathway Component
Disease
Mechanism
C1INH
Hereditary
Angioedema
Overproduction of C2b
(prokinin)
C1, C2, C4
Predisposition
to SLE
Opsonization of immune
complexes help keep
them soluble, deficiency
results in increased
precipitation in tissues
and inflammation
39
Complement Deficiencies and Disease
Lectin Pathway
Pathway Component
MBL
Disease
Susceptibility to
bacterial infections
in infants or
immunosuppressed
Mechanism
Inability to initiate
lectin pathway
40
Complement Deficiencies and Disease
Alternative Pathway
Pathway/Component
Disease
Mechanism
Factors B or D
Susceptibility
to pyogenic
(pus-forming)
bacterial
infections
Lack of sufficient
opsonization of bacteria
C3
Susceptibility
to bacterial
infections
Lack of opsonization and
inability to utilize the
membrane attack pathway
C5, C6, C7 C8, or
C9
Susceptibility
to Gramnegative
infections
Inability to attack the outer
membrane of Gramnegative bacteria
41
Complement Deficiencies and Disease
Alternative Pathway cont.
Pathway Component
Disease
Mechanism
Properdin (X-linked)
Susceptibility
meningococcal
meningitis
Lack of opsonization of
bacteria
Factors H or I
C3 deficiency
and
susceptibility to
bacterial
infections
Uncontrolled activation of
C3 via alternative
pathway resulting in
depletion of C3
42